PCM
SNDX icon

Peregrine Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Peregrine Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-199,086
Closed -$3.83M – 350
2024
Q3 		$3.83M Buy
199,086
+427
+0.2% +$8.82K 0.12% 239
2024
Q2 		$4.08M Buy
198,659
+2,580
+1% +$54K 0.12% 242
2024
Q1 		$4.67M Buy
196,079
+46
+0% +$1.03K 0.13% 237
2023
Q4 		$4.24M Sell
196,033
-23,941
-11% -$368K 0.13% 236
2023
Q3 		$3.19M Sell
219,974
-13,764
-6% -$260K 0.1% 242
2023
Q2 		$4.89M Buy
+233,738
New +$4.87M 0.13% 240

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Peregrine Capital Management's SNDX Position: Q4 2024 in Review

Peregrine Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 199,086 shares — an estimated $3.83M sold.

Peregrine Capital Management first reported a position in SNDX in Q2 2023 and held it in 6 quarters. The position peaked at $4.89M in Q2 2023. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • Peregrine Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Peregrine Capital Management sold 199,086 Syndax Pharmaceuticals shares in Q4 2024, an estimated $3.83M.
  • Peregrine Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Peregrine Capital Management's Syndax Pharmaceuticals position peaked at $4.89M in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on Peregrine Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.